Orexo AB (Sweden) Performance
| ORX Stock | SEK 9.55 0.15 1.60% |
The company holds a Beta of 0.75, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Orexo AB's returns are expected to increase less than the market. However, during the bear market, the loss of holding Orexo AB is expected to be smaller as well. At this point, Orexo AB has a negative expected return of -0.8%. Please make sure to check Orexo AB's skewness, and the relationship between the treynor ratio and rate of daily change , to decide if Orexo AB performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Orexo AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
| Begin Period Cash Flow | 504.1 M | |
| Total Cashflows From Investing Activities | -234.7 M |
Orexo |
Orexo AB Relative Risk vs. Return Landscape
If you would invest 1,648 in Orexo AB on August 25, 2024 and sell it today you would lose (693.00) from holding Orexo AB or give up 42.05% of portfolio value over 90 days. Orexo AB is producing return of less than zero assuming 2.6146% volatility of returns over the 90 days investment horizon. Simply put, 23% of all stocks have less volatile historical return distribution than Orexo AB, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Orexo AB Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Orexo AB's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Orexo AB, and traders can use it to determine the average amount a Orexo AB's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.306
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ORX |
Estimated Market Risk
| 2.61 actual daily | 23 77% of assets are more volatile |
Expected Return
| -0.8 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.31 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Orexo AB is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Orexo AB by adding Orexo AB to a well-diversified portfolio.
Orexo AB Fundamentals Growth
Orexo Stock prices reflect investors' perceptions of the future prospects and financial health of Orexo AB, and Orexo AB fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Orexo Stock performance.
| Return On Equity | -0.65 | |||
| Return On Asset | -0.0965 | |||
| Profit Margin | (0.28) % | |||
| Operating Margin | (0.29) % | |||
| Current Valuation | 795.36 M | |||
| Shares Outstanding | 34.35 M | |||
| Price To Earning | 14.08 X | |||
| Price To Book | 2.34 X | |||
| Price To Sales | 1.14 X | |||
| Revenue | 624.3 M | |||
| EBITDA | (116.3 M) | |||
| Cash And Equivalents | 697 M | |||
| Cash Per Share | 19.64 X | |||
| Total Debt | 519 M | |||
| Debt To Equity | 69.40 % | |||
| Book Value Per Share | 5.64 X | |||
| Cash Flow From Operations | (156.6 M) | |||
| Earnings Per Share | (6.28) X | |||
| Total Asset | 1.11 B | |||
| Current Asset | 845 M | |||
| Current Liabilities | 292 M | |||
About Orexo AB Performance
Assessing Orexo AB's fundamental ratios provides investors with valuable insights into Orexo AB's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Orexo AB is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Orexo AB , a specialty pharmaceutical company, develops products based on proprietary drug delivery technology. Orexo AB was founded in 1995 and is headquartered in Uppsala, Sweden. Orexo AB operates under Pharmaceuticals And Biosciences classification in Sweden and is traded on Stockholm Stock Exchange. It employs 130 people.Things to note about Orexo AB performance evaluation
Checking the ongoing alerts about Orexo AB for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Orexo AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Orexo AB generated a negative expected return over the last 90 days | |
| The company has kr519 Million in debt which may indicate that it relies heavily on debt financing | |
| The company reported the revenue of 624.3 M. Net Loss for the year was (183.9 M) with profit before overhead, payroll, taxes, and interest of 521.7 M. | |
| Orexo AB has accumulated about 697 M in cash with (156.6 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 19.64, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 17.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Orexo AB's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Orexo AB's stock is overvalued or undervalued compared to its peers.
- Examining Orexo AB's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Orexo AB's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Orexo AB's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Orexo AB's stock. These opinions can provide insight into Orexo AB's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Orexo Stock Analysis
When running Orexo AB's price analysis, check to measure Orexo AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Orexo AB is operating at the current time. Most of Orexo AB's value examination focuses on studying past and present price action to predict the probability of Orexo AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Orexo AB's price. Additionally, you may evaluate how the addition of Orexo AB to your portfolios can decrease your overall portfolio volatility.